Cross-sectional associations of albuminuria among Aboriginal and Torres Strait Islander adults: the eGFR Study

Nephrology

Volumn 23, Issue 1, 2018, Pages 37-45

  Hughes, J T ^a,b   Maple Brown, L J ^a,b   Thomas, M ^c   Lawton, P D ^a   Sinha, A ^d   Cass, A ^a   Barzi, F ^a   Jones, G R D ^e   Jerums, G ^f,g   MacIsaac, R J ^f,h   O'Dea, K ⁱ   Hoy, W E ^j  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b ROYAL DARWIN HOSPITAL   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d CAIRNS BASE HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g AUSTIN HEALTH   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ Centre for Population Health Research   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; TRIACYLGLYCEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ADULT; ALBUMINURIA; ARTICLE; AUSTRALIAN ABORIGINE; BLOOD PRESSURE; BODY MASS; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEMATURIA; HUMAN; LIVER FUNCTION TEST; MALE; OBESITY; PRESCRIPTION; PRIORITY JOURNAL; TORRES STRAIT ISLANDER; WAIST HIP RATIO; ABDOMINAL OBESITY; AUSTRALIA; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; GLOMERULUS FILTRATION RATE; HYPERTENSION; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCEANIC ANCESTRY GROUP; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; STATISTICAL MODEL;

ADIPOSITY; ADULT; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUSTRALIA; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; GLOMERULAR FILTRATION RATE; HEMATURIA; HUMANS; HYPERTENSION; KIDNEY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY, ABDOMINAL; OCEANIC ANCESTRY GROUP; PREVALENCE; RISK FACTORS;

EID: 85038120372     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12956     Document Type: Article

References (43)

1. Deckert T, Kofoed-Enevoldsen A, Nørgaard K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen T. Microalbuminuria: Implications for micro- and macrovascular disease. Diabetes Care 1992; 15 (9): 1181–1191.
2. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80 (1): 17–28.
3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal Follow-up and Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care Organization. Arch. Intern. Med. 2004; 164 (6): 659–663.
4. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 2006; 23 (5): 469–480.
5. Johnson DW, Atai E, Chan M et al. KHA-CARI Guideline: Early chronic kidney disease: Detection, prevention and management. Nephrol. Ther. 2013; 18 (5): 340–350.
6. CARPA. Chronic kidney disease. In: CARPA Standard Treatment Manual, 6th edn. Alice Springs: Centre for Remote Health, 2014; 282–285.
7. Maple-Brown L, Cunningham J, Hodge A et al. High rates of albuminuria but not of low eGFR in Urban Indigenous Australians: the DRUID Study. BMC Public Health 2011; 11 (1): 346.
8. Lawton PD, Cunningham J, Hadlow N, Zhao Y, Jose MD. Chronic kidney disease in the Top End of the Northern Territory of Australia, 2002-2011: a retrospective cohort study using existing laboratory data. BMC Nephrol. 2015; 16: 168.
9. Hoy WE, Wang Z, van Buynder P, Baker PRA, McDonald SM, Mathews JD. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int. 2001; 60 (1): 249–256.
10. Australian Institute of Health and Welfare 2011. The health and welfare of Australia's Aboriginal and Torres Strait Islander people, an overview 2011. Cat. no. IHW 42. Canberra: AIHW. [Access date: 22 Agust 2016]. Available from: http://www.aihw.gov.au/indigenous-observatory/health-and-welfare/.
11. Australian Government Department of Health (2013). Medicare Health Assessment for Aboriginal and Torres Strait Islander People- MBS item 715, October 2013. Commonwealth of Australia, Canberra. [Access date 22 August 2016]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/mbsprimarycare_ATSI_MBSitem715.
12. Maple-Brown L, Lawton P, Hughes J et al. Study Protocol-accurate assessment of kidney function in Indigenous Australians: aims and methods of the eGFR study. BMC Public Health 2010; 10: 80.
13. Cass A, Cunningham J, Wang Z, Hoy W. Regional variation in the incidence of end-stage renal disease in Indigenous Australians. Med. J. Aust. 2001; 175 (1): 24–27.
14. Horton D. Australian Institute of Aboriginal and Torres Strait Islander Studies. In: Horton D (ed). The Encyclopedia of Aboriginal Australia: Aboriginal and Torres Strait Islander History, Society and Culture. Canberra: Aboriginal Studies Press for the Australian Institute of Aboriginal and Torres Strait Islander Studies, 1994; 1089.
15. O'Neal DN, Piers LS, Iser DM et al. Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis 2008; 201 (2): 368–377.
16. Australian Bureau of Statistics. (2013). Estimates of Aboriginal and Torres Strait Islander Australians, June 2011 (cat. no. 3238.0.55.001). [Access date: 18 May 2016]. Available from: http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3238.0.55.001Main+Features1June%202011?OpenDocument
17. Selvin E, Steffes MW, Gregg E, Brancati FL, Coresh J. Performance of A1C for the Classification and Prediction of Diabetes. Diabetes Care 2011; 34 (1): 84–89.
18. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Resetting the Hypertension Sails. Circulation 2003; 107 (24): 2993–2994.
19. National Health and Medical Research Council. NHMRC Australian Guidelines to reduce health risks from drinking alcohol. Commonwealth of Australia: National Health and Medical Research Council; 2009 [Available from: http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ds10-alcohol.pdf].
20. Australian Bureau of Statistics. Remoteness Structure. 2014. http://www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure.
21. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am. Fam. Physician 2004; 70 (6): 1091–1097.
22. Hughes JT, Maple-Brown LJ, Piers LS, Meerkin J, O'Dea K, Ward LC. Development of a single frequency bioimpedance prediction equation for fat-free mass in an adult Indigenous Australian population. Eur. J. Clin. Nutr. 2015; 69: 28–33.
23. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am. J. Clin. Nutr. 2000; 72 (3): 694–701.
24. Maple-Brown LJ, Hughes JT, Lawton PD et al. Accurate Assessment of Kidney Function in Indigenous Australians: The Estimated GFR Study. Am. J. Kidney Dis. 2012; 60 (4): 680–682.
25. Lee DS, Evans JC, Robins SJ et al. Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk: The Framingham Heart Study. Arterioscler. Thromb. Vasc. Biol. 2007; 27 (1): 127–133.
26. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Noncommunicable Disease Surveillance, WHO, 1999.
27. Kim MK, Baek KH, Kang MI et al. Serum alkaline phosphatase, body composition, and risk of metabolic syndrome in middle-aged Korean. Endocr. J. 2013; 60 (3): 321–328.
28. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6 (1): 1–7.
29. Wang Z, Hoy W, Wang Z. The correlates of urinary albumin to creatinine ratio (ACR) in a high risk Australian aboriginal community. BMC Nephrol. 2013: 14(176).
30. D'Onise K, McDermott RA, Campbell SK. Benefits of modest weight or waist circumference loss in a remote North Queensland Indigenous population. Aust. N. Z. J. Public Health 2013; 37 (4): 345–349.
31. O'Dea K, White N, Sinclair A. An investigation of nutrition-related fators in an isolated Aboriginal community in Northern Australia: advantages of a traditionally-oriented life-style. Med. J. Aust. 1988; 148: 177–180.
32. Rowley KG, Iser DM, Best JD, O'Dea K, Leonard D, McDermott R. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia 2000; 43 (11): 1397–1403.
33. Piers LS, Rowley KG, Soares MJ, O'Dea K. Relation of adiposity and body fat distribution to body mass index in Australians of Aboriginal and European ancestry. Eur. J. Clin. Nutr. 2003; 57 (8): 956–963.
34. Rutishauser I, McKay H. Anthropometric status and body composition in Aboriginal women of the Kimberley region. Med. J. Aust. 1986; 144: S8–10.
35. Mendham AE, Coutts AJ, Duffield R. The acute effects of aerobic exercise and modified rugby on inflammation and glucose homeostasis within Indigenous Australians. Eur. J. Appl. Physiol. 2012; 112 (11): 3787–3795.
36. Heitmann BL, Swinburn BA, Carmichael H et al. Are there ethnic differences in the association between body weight and resistance, measured by bioelectrical impedance? Int. J. Obes. (Lond) 1997; 21 (12): 1085–1092.
37. Yki-Jarvinen H, Koivisto VA, Karonen SL. Influence of body composition on insulin clearance. Clin. Physiol. 1985; 5 (1): 45–52.
38. Yusuf S, Hawken S, Ôunpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364 (943): 937–952.
39. McDonald S. Incidence and treatment of ESRD among indigenous people of Australasia. Clin. Nephrol. 2010; 73 (S1): S28–S31.
40. Moore L, Lloyd M, Pugsley D, Seymour A. Renal Disease in the Australian Aboriginal population: a pathological study. Nephrol. 1996; 2: 315–321.
41. Hoy WE, Norman RJ, Hayhurst BG, Pugsley DJ. A health profile of adults in a Northern Territory aboriginal community, with an emphasis on preventable morbidities. Aust. N. Z. J. Public Health 1997; 21 (2): 121–126.
42. Strippoli GFM, Bonifati C, Craig ME, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst. Rev. 2006; 4.
43. Hoy WE, Wang Z, Baker PRA, Kelly AM. Secondary Prevention of Renal and Cardiovascular Disease: Results of a Renal and Cardiovascular Treatment Program in an Australian Aboriginal Community. J. Am. Soc. Nephrol. 2003; 14(Supplement 2): S178-85.